Hansoh MET Combination Improves PFS After EGFR Therapy

Company Hansoh Pharma Event Type Phase 3 data disclosure Modality Oral MET inhibitor plus third-generation EGFR inhibitor Asset Dalmelitinib plus aumolertinib (HS-10241-301) Target MET; EGFR Disease Area EGFR-mutant, MET-amplified NSCLC after EGFR-TKI failure Summary Hansoh disclosed a statistically significant PFS result for dalmelitinib plus aumolertinib…